Bavarian Nordic defies new failure and maintains efforts in cancer area
Even though Bavarian Nordics' phase II trial with a vaccine candidate against the cancer disease chordoma failed, the firm's management sees enough potential within the oncology portfolio to keep the work going, although it is still uncertain how this will pan out.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
In recent years, Bavarian Nordic has had some trouble in the cancer area with three failures to follow. Firstly, Prostvac, then CV301 and in December 2020 BN-Brachyury failed as a therapeutic vaccine against he rare cancer disease chordoma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
